N@N

Cubist Pharmaceuticals to Present at November Investor Conferences

^{Published on 2010-10-26 10:11:08 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that company management will participate in three investor conferences during November to discuss the companya™s business activities, financial outlook, and current news.

• David McGirr, SVP and CFO, will present on Wednesday, November 3, at 10:50 a.m. Eastern Time, at the Oppenheimer 21^st Annual Healthcare Conference being held at the Waldorf Astoria in New York City. (Live audio with slides webcast)
• Robert Perez, EVP and COO, will host one-on-one meetings on Tuesday, November 16, at the Jefferies 2010 Boston Healthcare Summit being held at the Boston Harbor Hotel in Boston
• Mr. McGirr also will present on Wednesday, November 17, at 3:15 p.m. Eastern Time, at Lazard Capital Markets 7^th Annual Healthcare Conference being held at The St. Regis in New York City. (Live audio with slides webcast)

Both of Mr. McGirra™s presentations will be accessible live through Cubista™s website at [ www.cubist.com ] in the Investor Relations Conference Calendar section and will remain available there for a period of 30 days after the presentations.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; and a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea). Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.